To the Editor: The substantial weight gain, lipid elevations, and other metabolic abnormalities associated with 12 weeks of second-generation antipsychotic medication use among youth in the cohort study by Dr Correll and colleagues1 was alarming. As discussed in the accompanying Editorial by Drs Varley and McClellan,2 lower-risk alternatives should be considered before prescribing atypical antipsychotic medications in children, especially given cardiometabolic risks and unclear efficacy for certain psychiatric disorders. However, behavioral and psychotherapeutic alternatives were not mentioned.
Lewin AB, Storch EA, Storch HD. Risks From Antipsychotic Medications in Children and Adolescents. JAMA. 2010;303(8):729-731. doi:10.1001/jama.2010.132